- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05361980
Sicherheit und Wirksamkeit von pädiatrischen orthopädischen Implantaten (Global POISE)
Klinisches Nachsorgeprogramm zur prospektiven Beobachtung der Sicherheit und Wirksamkeit von Implantaten
Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity.
Given the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy.
Prospective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
STUDY PROCEDURES Screening Patients will be screened against basic inclusion/exclusion criteria to see if patients may be appropriate for study participation according to any standard of care assessments available, and where appropriate with the site's REB/IRB screening procedures and local regulatory requirements. If a patient is deemed eligible, data outlined throughout this protocol will be collected, de-identified and entered into a Research Electronic Database Capture (REDCap) system managed at BCCH.
Enrollment Patients will be assigned a sequential, unique study number (subject ID) and de-identified data will be entered in the study database. The center number is designated by the BCCH team for each individual investigational site. The patient number will be in sequential order by the patient screening date starting with 001. Once a patient has been assigned a subject ID, the number will not be reused.
Pre-Operative Procedures Once a patient is identified as eligible for an Implant Safety and Efficacy device report, it will be determined whether that patient is already enrolled in one of the existing condition-specific registries. Should participants be enrolled in a condition-specific registry, demographic data, medical history, preoperative clinical data, including any pre-existing infections at or near the operative site, and data on pre-operative radiographs for the relevant underlying diagnosis will have already been prospectively collected under registry procedures. If a patient has not been previously enrolled in a condition-specific registry, the patient will be offered enrollment in both the condition registry and for the purposes of the Implant Safety and Efficacy device report. Demographic data, medical history, preoperative clinical data and data on pre-operative radiographs for the relevant underlying diagnosis will then be collected retrospectively from the medical record.
Required Data Collection:
Operative details in the source documentation will be collected that provide specific information from the subject's surgery such as surgical approach, complications, and unique device identification (UDI) numbers for the implanted device.
The following data will be collected and entered into the registry:
- Operative data, specific to the technique related to the relevant OrthoPediatrics system/device
- Assessments of any device-related adverse events
- Assessment for other adverse events
- When possible, the UDI number for the device(s) implanted, or information on the device implanted
Follow-up Procedures
Data collected during routine standard of care follow-up visits will be collected as part of this study. The following data will be collected:
- Radiographs obtained during study clinical evaluations to determine bony union, as well as healing or complications
- Device-related adverse events
- Unanticipated device-related serious adverse device effects
- Information on implant removals not related to an adverse event; degree of bony union just prior to implant removal Unscheduled Visits [if or when needed]
The condition-specific registries are designed to capture every visit that occurs, whether scheduled or unscheduled. An unscheduled visit may occur when an adverse event occurs, or when a patient returns outside of the planned interval window. If an unscheduled visit occurs, the following assessments are to be done:
- Assessment of any adverse events related to the device
- Survivorship of the device
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Harpreet Chhina, PhD
- Telefonnummer: 6008 604-875-2000
- E-Mail: hchhina@cw.bc.ca
Studieren Sie die Kontaktsicherung
- Name: Bryn Zomar, PhD
- Telefonnummer: 604-875-2359
- E-Mail: bryn.zomar@cw.bc.ca
Studienorte
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3N1
- Rekrutierung
- BC Children's Hospital
-
Kontakt:
- Emily Schaeffer, PhD
- Telefonnummer: 604-875-2359
- E-Mail: emily.schaeffer@cw.bc.ca
-
Hauptermittler:
- Anthony Cooper, FRCSC
-
Hauptermittler:
- Kishore Mulpuri, FRCSC
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Anyone who meets the eligibility criteria and is within the age limits listed in the above sections can participate in this study.
Beschreibung
Inclusion Criteria:
- Patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. Off-label use is strongly discouraged; however, any and all on- and off-label indications for use of the products in this program will be collected and stratified accordingly
- Patients must be able to adhere to the required length of follow-up for the endpoints of each individual product
- Informed consent/assent is required
Exclusion Criteria:
- Patients with a demonstrated sensitivity to metals
- Patients with an inability to follow a post-operative regimen
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Longitudinal Observational Group
Pediatric patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. |
Patient receives a pediatric orthopaedic implant as a part of standard clinical care. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Device related adverse events
Zeitfenster: 2 years post implant insertion
|
Determine the frequency and severity of device-related adverse events at device-specific end points. All adverse events will be recorded and followed during the study. The frequency and severity of device related adverse events will be analyzed to ensure the device risk profile has not changed. |
2 years post implant insertion
|
|
Implant survival
Zeitfenster: 2 years post implant insertion
|
Determine the implant survival rate at post-operative end-point: (lack of revision) |
2 years post implant insertion
|
|
Implant efficacy
Zeitfenster: 2 years post implant insertion
|
Efficacy will be assessed by post-operative clinical and radiographic evaluations at each follow-up end-point to assess bone fixation and/or deformity correction. |
2 years post implant insertion
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Numeric pain rating scale (NPRS)
Zeitfenster: 2 years post implant insertion
|
The numeric pain rating scale (NPRS) is a subjective, 11-point numerical scale in which respondents self-report their pain on a scale of 0 (no pain at all) to 10 (worst pain imaginable). |
2 years post implant insertion
|
|
LIMB-Q Kids
Zeitfenster: 2 years post implant insertion
|
LIMB-Q Kids is a new patient reported outcome measure (PROM) for children with lower limb deformities. |
2 years post implant insertion
|
|
PROMIS
Zeitfenster: 2 years post implant insertion
|
The Patient Reported Outcomes Measurement Information System (PROMIS) measures are self-reported and parent-reported. It includes over 300 measures of global, physical, mental, and social health for adults and children in the general population and those living with a chronic condition. Specifically, the PROMIS Global Health will be administered to all patients while the PROMIS Physical Function - Mobility short form will be administered to those with an implant used in a lower extremity and the PROMIS Physical Function - Upper Extremity short form will be administered to those with an implant used in an upper extremity. |
2 years post implant insertion
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Bryn Zomar, PhD, University of British Columbia
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Wunden und Verletzungen
- Neubildungen
- Gelenkerkrankungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Leukämie, lymphatisch
- Leukämie
- Hüftverletzungen
- Gelenkluxationen
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Hämische und lymphatische Krankheiten
- Angeborene Anomalien
- Frakturen, Knochen
- Vorläuferzelle lymphoblastische Leukämie-Lymphom
- Erkrankungen des Bewegungsapparates
- Hüftluxation
Andere Studien-ID-Nummern
- H21-03076
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .